Canaccord Genuity Reiterates Buy Rating on HELP
Canaccord Genuity maintains its buy rating on HELP, setting a $42 price target, a 546.14% upside from the current price.
Key Points
- Canaccord Genuity reiterated its buy rating on HELP, setting a price target of $42 as of July 1, 2026.
- Canaccord Genuity's $42 price target implies 546.14% upside from Cybin D/B/A Helus Pharma's ($HELP) current $6.50 share price.
- Shares of HELP traded near $6.94 on Wednesday, reflecting investor interest following recent analyst updates.
- Other institutions like Venrock Adviser and Millennium Management adjusted their holdings in HELP.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
On July 1, 2026, Canaccord Genuity reiterated its buy rating on HELP with a price target of $42. Analyst Sumant Kulkarni maintained this optimistic outlook, suggesting confidence in the company's potential.
Canaccord Genuity vs. the S&P 500
Hypothetical, simulated performance of disclosed positions vs. the S&P 500. Not realized profit and not investment advice. Past performance does not indicate future results. Details.
Other Institutional Activity in HELP
Several institutional investors have adjusted their positions in HELP. Venrock Adviser, LLC increased its holdings by 11,404 shares, bringing its total to 3,851,654 shares valued at approximately $18.49 million. Millennium Management LLC made a significant move, adding 1,387,292 shares, resulting in a total of 2,415,841 shares worth about $11.60 million, marking a 134.9% increase. On the other hand, Orbimed Advisors LLC trimmed its position by 7,657 shares, now holding 3,832,843 shares valued at $18.40 million. Acorn Capital Advisors, LLC and Rosalind Advisors, Inc. also reduced their holdings by 32,757 and 125,726 shares, respectively.
Cybin D/B/A Helus Pharma Stock Down 46.6%
Shares of HELP traded near $6.94 on Wednesday. The company has seen various institutional activities, reflecting diverse investor strategies. While specific market cap and P/E ratio details are not available, the stock has been receiving attention from analysts, as indicated by the reiterated buy rating from Canaccord Genuity.
$HELP price target
Past daily closes and this analyst's 12-month price target. Not investment advice.
Analysts Set New Price Targets
On July 1, 2026, Canaccord Genuity maintained its buy rating on HELP with a $42 price target. Earlier, on April 13, 2026, TD Cowen initiated coverage with a buy rating and an $8 target. HC Wainwright & Co. also maintained a buy rating with a $95 target on March 2, 2026. The consensus among analysts suggests a positive outlook for HELP, with a general buy recommendation.
About HELP
HELP is a company involved in [industry/sector] activities. While detailed information about its operations and leadership is not provided, the company is actively followed by investors and analysts, indicating its relevance in the market.
Bottom Line
Canaccord Genuity's reiterated buy rating and $42 price target for HELP underscore a positive outlook from analysts. Institutional investors are actively adjusting their positions, reflecting varied strategies and confidence levels. As always, these insights are based on backward-looking data and past filings, which may not represent the current situation.
Get Cybin D/B/A Helus Pharma alerts
New 13F filings, insider trades, and analyst moves on $HELP, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.